Join
Live feed
·
PRReleasevia Quantisnow
Advaxis, Inc. logo
OS Therapies Incorporated logo

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline

ByQuantisnow·Wall Street's wire, on your screen.
ADXS· Advaxis, Inc.OSTX· OS Therapies Incorporated
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ADXS (Advaxis, Inc.), OSTX (OS Therapies Incorporated) and more on Quantisnow.

OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostrate Cancer Programs to Pipeline | Quantisnow